Copenhagen-based biotech SNIPR Biome has raised €35 million in Series B funding to accelerate its portfolio of CRISPR-based microbial gene therapies aimed at tackling antimicrobial resistance and difficult-to-treat infections.
The round brings in new investors including the Cystic Fibrosis Foundation and Germany’s Federal Agency for Breakthrough Innovation (SPRIN-D), while existing backers Lundbeckfonden BioCapital, North-East Family Office, and Wellington Partners also participated. It follows a €20 million venture debt agreement with the European Investment Bank secured in late 2024.
The fresh capital will support:
• Advancement of a CRISPR-Cas therapy targeting Pseudomonas aeruginosa airway infections in cystic fibrosis patients.
• Development of novel interventions to eliminate antibiotic resistance genes across bacterial species in humans.
• Continued clinical progress for SNIPR001, the company’s lead candidate designed to prevent bloodstream infections in hematologic cancer patients, now in Phase 1b trials at eight U.S. cancer centers.
SNIPR Biome is also engaged in partnerships with CARB-X, the Gates Foundation, IPATH, SPRIN-D, and MD Anderson Cancer Center.
Founded by Christian Grøndahl, the company was the first to deliver an oral CRISPR-based therapeutic to humans. It holds both U.S. and European patents covering microbiome-targeted CRISPR applications. Its technology enables precision targeting of harmful bacteria while sparing beneficial microbiota — a key advantage over broad-spectrum antibiotics.
“This financing marks a pivotal milestone as we advance SNIPR001 and expand our infectious disease pipeline targeting high-priority pathogens,” said Grøndahl, CEO and co-founder.
With antimicrobial resistance projected to claim 10 million lives annually by 2050, SNIPR Biome positions itself at the forefront of infectious disease innovation, aiming to replace conventional antibiotics with gene-editing precision therapies.
